Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1372 studies found for:    Multiple Sclerosis
Show Display Options
RSS Create an RSS feed from your search for:
Multiple Sclerosis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
2 Recruiting Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Procedure: Multiple Sclerosis Functional Composite;   Procedure: Mobile Multiple Sclerosis Functional Composite
3 Completed
Has Results
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: RNF;   Drug: Placebo
4 Completed
Has Results
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
Condition: Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate (DB);   Drug: Placebo;   Drug: Glatiramer Acetate (OL)
5 Terminated Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Device: Trap Myelin Test
6 Enrolling by invitation Effects of Acthar on Recovery From Cognitive Relapses in MS
Condition: Multiple Sclerosis
Intervention: Drug: Adrenocorticotropic Hormone
7 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
8 Unknown  Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Physical exercise training
9 Recruiting Physical Telerehabilitation in Veterans With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Device: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system
10 Recruiting Effects of the Cross-Training in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Weakness;   Fatigue
Interventions: Other: Cross-Training healthy subjects;   Other: Cross-Training multiple sclerosis;   Other: Standard-training multiple sclerosis
11 Completed
Has Results
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Atorvastatin;   Drug: Placebo
12 Completed
Has Results
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Placebo
13 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
14 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab;   Biological: Interferon beta-1a
15 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a
16 Completed
Has Results
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
17 Completed
Has Results
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
18 Completed Supported Treadmill Training for Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Body-weight supported treadmill training
19 Active, not recruiting Gene Expression Profiles in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Procedure: Blood Draw
20 Completed
Has Results
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
Condition: Multiple Sclerosis
Intervention: Drug: Rebif® New Formulation (RNF) using RebiSmartTM

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years